Who Owns Contineum Therapeutics Stock?
NASDAQ: CTNMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Ownership breakdown
- Held by institutions
- 100.00%
- Institutions (% of float)
- 100.06%
- Held by insiders
- 0.06%
- Institutional holders
- 157
- Institutions 99.9%
- Insiders 0.1%
- Public and other 0.0%
Who owns Contineum Therapeutics stock?
Institutional investors own about 100.0% of Contineum Therapeutics's shares, spread across 157 institutions that file 13F reports. That level of institutional ownership is high, typical of large, widely followed companies. Insiders, including executives, directors and large founding shareholders, hold 0.06% of CTNM.
The largest institutional holders are Montanova Capital LLC (7.96%), FMR, LLC (7.38%) and Blackrock Inc. (6.29%). Together, the top 10 institutions control 54.0% of shares outstanding. In their latest filings, 6 of the top 10 institutions increased their CTNM positions and 3 reduced them.
Summary generated from market data by MetaCap's automated system. Methodology
Top institutional holders of CTNM
| Institution | Shares | % Held | Change |
|---|---|---|---|
| Montanova Capital LLC | 2.81M | 7.96% | -0.9% |
| FMR, LLC | 2.61M | 7.38% | +150.9% |
| Blackrock Inc. | 2.22M | 6.29% | +7.7% |
| Johnson & Johnson | 1.98M | 5.60% | 0.0% |
| Janus Henderson Group Ltd. | 1.72M | 4.87% | -37.0% |
| Franklin Templeton, Inc. | 1.70M | 4.82% | -7.3% |
| Balyasny Asset Management LP | 1.70M | 4.80% | +11.3% |
| Trails Edge Capital Partners, LP | 1.69M | 4.79% | +100.0% |
| Vanguard Capital Management LLC | 1.36M | 3.85% | +3.1% |
| Versant Venture Management, LLC | 1.29M | 3.66% | +138.2% |
% held is the share of total shares outstanding. Change is the percentage change in the position since the holder's previous 13F filing.
Top mutual fund and ETF holders of CTNM
| Fund | Shares | % Held |
|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 982.26K | 2.78% |
| iShares Trust-iShares Russell 2000 ETF | 717.28K | 2.03% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 625.15K | 1.77% |
| Fidelity Select Portfolios-Select Pharmaceuticals Portfolio | 614.20K | 1.74% |
| Fidelity Advisor Series VII-Fidelity Advisor Biotechnology Fund | 481.90K | 1.36% |
| Fidelity Select Portfolios-Select Health Care Portfolio | 450.00K | 1.27% |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | 308.75K | 0.87% |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | 297.23K | 0.84% |
| Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund | 280.00K | 0.79% |
| iShares Trust-iShares Russell 2000 Value ETF | 256.27K | 0.72% |
Frequently asked questions
Who is the largest shareholder of Contineum Therapeutics?
Montanova Capital LLC is the largest institutional shareholder of CTNM, owning 7.96% of shares outstanding (2.81M shares) as of its latest 13F filing.
What percentage of Contineum Therapeutics is owned by institutions?
Institutions own about 100.0% of CTNM shares and 100.1% of the public float.
How much of Contineum Therapeutics do insiders own?
Insiders, such as officers and directors, own about 0.06% of CTNM shares outstanding.
Where does institutional ownership data come from?
Investment managers with more than $100 million in US equities must file Form 13F with the SEC within 45 days of each quarter-end. Holdings are therefore up to about 4.5 months old when published.